Nikolaus Osterrieder

Nikolaus Osterrieder

Auto-generated profile, based on publicly available information

Nikolaus Osterrieder

Institut für Virologie, Freie Universität Berlin, 14163 Berlin, Germany

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in BioTechniques
Verified
Journal Article
Open access
BKB. Karstentischer
B. Karstentischer
JEJens von Einem
Jens von Einem
BKBenedikt B. Kaufer
Benedikt B. Kaufer
NONikolaus Osterrieder
Nikolaus Osterrieder
Red recombination using PCR-amplified selectable markers is a well-established technique for mutagenesis of large DNA molecules in Escherichia coli. The system has limited efficacy and versatility,... BAC Recombineering Straightforward modification of BAC-cloned sequences is critical for generating transgenic animals and for functional studies of DNA viruses. Although a number of methods for mar...

19 March 2010
Verified
Book Chapter
Closed access
PDF file
BTB. Karsten Tischer
B. Karsten Tischer
GSGregory Smith
Gregory Smith
NONikolaus Osterrieder
Nikolaus Osterrieder

1 April 2006 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
NONikolaus Osterrieder
Nikolaus Osterrieder
JKJeremy Kamil
Jeremy Kamil
DSDaniel Schumacher
Daniel Schumacher
BTB. Karsten Tischer
B. Karsten Tischer
STSascha Trapp
Sascha Trapp

1 November 2020 in Cell
Verified
Journal Article
Open access
JKJakob Kreye
Jakob Kreye
SRS. Momsen Reincke
S. Momsen Reincke
HKHans-Christian Kornau
Hans-Christian Kornau
ESElisa Sánchez-Sendin
Elisa Sánchez-Sendin
VCVictor M Corman
Victor M Corman
HPHarald Prüss
Harald Prüss
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

27 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DCDavid J. Chen
David J. Chen
NONikolaus Osterrieder
Nikolaus Osterrieder
SMStephan M. Metzger
Stephan M. Metzger
EBElizabeth Buckles
Elizabeth Buckles
ADAnne M. Doody
Anne M. Doody
David A. PutnamDavid A. Putnam
David A. Putnam
As new disease threats arise and existing pathogens grow resistant to conventional interventions, attention increasingly focuses on the development of vaccines to induce protective immune responses. Given their admirable safety records, protein subunit vaccines are attractive for widespread immunization, but their disadvantages include poor immunogenicity and expensive manufacture. We show here that engineered Escherichia coli outer membrane vesicles (OMVs) are an easily purified vaccine-delivery system capable of greatly enhancing the immunogenicity of a low-immunogenicity protein antigen without added adjuvants. Using green-fluorescent protein (GFP) as the model subunit antigen, genetic fusion of GFP with the bacterial hemolysin ClyA resulted in a chimeric protein that elicited strong anti-GFP antibody titers in immunized mice, whereas immunization with GFP alone did not elicit such titers. Harnessing the specific secretion of ClyA to OMVs, the ClyA-GFP fusion was found localized in OMVs, resulting in engineered recombinant OMVs. The anti-GFP humoral response in mice immunized with the engineered OMV formulations was indistinguishable from the response to the purified ClyA-GFP fusion protein alone and equal to purified proteins absorbed to aluminum hydroxide, a standard adjuvant. In a major improvement over current practice, engineered OMVs containing ClyA-GFP were easily isolated by ultracentrifugation, effectively eliminating the need for laborious antigen purification from cell-culture expression systems. With the diverse collection of heterologous proteins that can be functionally localized with OMVs when fused with ClyA, this work signals the possibility of OMVs as a robust and tunable technology platform for a new generation of prophylactic and therapeutic vaccines.

27 November 2017 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JCJessica J. Chiang
Jessica J. Chiang
KSKonstantin M. J. Sparrer
Konstantin M. J. Sparrer
MGMichiel van Gent
Michiel van Gent
CLCharlotte Lässig
Charlotte Lässig
THTeng Huang
Teng Huang
MGMichaela Gack
Michaela Gack
The sensor RIG-I detects double-stranded RNA derived from RNA viruses. Although RIG-I is also known to have a role in the antiviral response to DNA viruses, physiological RNA species recognized by RIG-I during infection with a DNA virus are largely unknown. Using next-generation RNA sequencing (RNAseq), we found that host-derived RNAs, most prominently 5S ribosomal RNA pseudogene 141 (RNA5SP141), bound to RIG-I during infection with herpes simplex virus 1 (HSV-1). Infection with HSV-1 induced relocalization of RNA5SP141 from the nucleus to the cytoplasm, and virus-induced shutoff of host protein synthesis downregulated the abundance of RNA5SP141-interacting proteins, which allowed RNA5SP141 to bind RIG-I and induce the expression of type I interferons. Silencing of RNA5SP141 strongly dampened the antiviral response to HSV-1 and the related virus Epstein-Barr virus (EBV), as well as influenza A virus (IAV). Our findings reveal that antiviral immunity can be triggered by host RNAs that are unshielded following depletion of their respective binding proteins by the virus.